Icosavax
Public CompanyIcosavax develops virus-like particle vaccines targeting respiratory viruses such as RSV, hMPV, and COVID-19. Its platform uses computational protein design and virus-like particle scaffolds to create experimental vaccines intended to be shelf-stable and advance to clinical trials.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Vaccines, Life Sciences
- Status
- Public Company
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
-
Completed an acquisition or disposition Feb 20, 2024
-
Leadership or executive-pay change Feb 20, 2024
-
Signed a material agreement Dec 12, 2023
-
Signed a material agreement May 23, 2023
-
Leadership or executive-pay change Feb 11, 2022
-
Leadership or executive-pay change Jan 5, 2022
-
Signed a material agreement Dec 16, 2021
-
Filed to go public Jul 7, 2021
People
-
Neil King Co-founder